Chronic lung diseases pose a tremendous global burden. At least one in four people suffer
from severe pulmonary sequelae over the course of a lifetime. Despite substantial …

The immune system is receiving increasing attention for interstitial lung diseases, as
knowledge on its role in fibrosis development and response to therapies is expanding …

Abstract Background Coronavirus disease 2019 (COVID‐19) is a pandemic that has rapidly
spread worldwide. Increasingly, confirmed patients being discharged according to the …

Rationale: Pulmonary hypertension (PH) is a common, severe comorbidity in interstitial lung
diseases such as pulmonary fibrosis (PF), and it has limited treatment options. Excessive …

Background: One of the greatest challenges for medicine is to find a safe and effective
treatment for immune-related diseases. However, due to the low efficacy of the treatment …

Idiopathic pulmonary fibrosis (IPF) is characterised by an important remodelling of lung
parenchyma. Current evidence indicates that the disease is triggered by alveolar epithelium …

Idiopathic pulmonary fibrosis (IPF) is a major cause of respiratory failure in critically ill
patients and common outcome of various lung interstitial diseases. Its mortality remains …

In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan city, Hubei province,
China. Rapidly escalated into a worldwide pandemic, it has caused an unprecedented and …

Mesenchymal Stem Cells (MSCs) represent a heterogeneous group of self-renewal,
multipotent non-hematopoietic stem cells, which display profound immunomodulatory …

Mesenchymal stromal cells (MSCs) as a kind of pluripotent adult stem cell have shown great
therapeutic potential in relation to many diseases in anti-inflammation and regeneration. The …